BENNOUNA , J.

Last name: BENNOUNA

First name: J.

September 8, 2017 (v1)

Conference paper

Metadata-only

Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

Bennouna, J. Hiret, S. Borg, C.

International audience

Uploaded on: March 26, 2023
2014 (v1)

Journal article

Metadata-only

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

Samalin, E. Bouche, O. Thezenas, S.

BACKGROUND: This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), who had progressed after irinotecan-based chemotherapy. METHODS: In Phase I, in a 3+3 dose escalation schedule, patients received...

Uploaded on: December 4, 2022
September 8, 2017 (v1)

Conference paper

Metadata-only

Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial

Aparicio, T. Bennouna, J. Malicot, K. Le

International audience

Uploaded on: February 28, 2023
April 2019 (v1)

Journal article

Metadata-only

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)

Adenis, Antoine Bennouna, J. Etienne, P.L.

PURPOSE:The role of chemotherapy has not been established in the treatment of metastatic squamous cell oesophageal cancer (mESCC).PATIENTS AND METHODS:E-DIS is a discontinuation trial, aimed at estimating efficacy, quality of life and safety of chemotherapy continuation (CT-CONT) in patients with mESCC who are free from progression after a...

Uploaded on: December 4, 2022

BENNOUNA , J.

Recent uploads